Full Description
The book studies the pharmaceutical industry of India. It is one of the most successful stories of economic expansion and improvements in public health. Indian firms have made access to quality medicines possible and affordable in many developing countries. Indian pharmaceuticals are also exported on a large scale to the United States and other highly regulated markets. A wave of mergers, acquisitions and tie-ups point to growing integration between Indian firms and global pharma multinationals.
Please note: Taylor & Francis does not sell or distribute the Hardback in India, Pakistan, Nepal, Bhutan, Bangladesh and Sri Lanka
Contents
1. Introduction - Hans Lofgren Section I: Industry development and structure 2. The Indian pharma industry: history and structure - Manohar Rao 3. Generics production and trade - Deepak Kumar Jena et al. 4. Environmental and social implications - G. Vijay 5. German pharma companies in India -- Christine Fischer et al. Section II: Regulatory environment 6. Medicines access and public health 7. Quality, safety, and efficacy regulation 8. Price control and drug affordability - Prabodh Malhotra Section III: Intellectual property rights and TRIPS flexibilities 9. Compulsory licensing 10. Utilising TRIPS flexibilities - Narayanan Lalitha 11. Novartis and legal battle for access to medicines - Gopal Dabade Section IV: Global challenges and international precedents 12. RD in India: alternative RD funding models - Phil Soos 13. Access to medicines in developing economies by competition law - Tu Thanh Nguyen 14. Implications of the Indian Patent Law on Access to Antiretroviral Drugs in Sub-Saharan Africa -Christine Fischer 15. Politics of AIDS treatment in Brazil - Andre de Mello e Souza 16. Conclusion
